Bae Byuongjun – President, KoNECT, South Korea
Dr Bae Byuongjun, president of the Korea National Enterprise for Clinical Trials (KoNECT), outlines why Korea stands out in the APAC region as a top clinical trial destination, how clinical…
Address: 101 Daehakno, Chongno-gu, Seoul 110-799, Republic of Korea
Tel: 82.2.3668.7610
In response to increase in demand for clinical trials, KoNECT was founded for regional balanced development of medical industry, development of human force for clinical trials and development of core technologies. KoNECT has been designated by the Ministry for Health, Welfare and Family Affairs to be entrusted by the state the responsibilities and authority for budget distribution and management targeting researchers equipped with the capacities of research planning, promotion and management. For administration of supporting businesses, KoNECT is organized with 3 groups in order to implement infrastructures for clinical trials. In other words, KoNECT is divided into Regional Clinical Trials Center Supporting Group for implementation of facilities and equipments in clinical trial centers, Clinical Trials Training Academy for development and training of professional human force for clinical trials and Development Group for Clinical Trials Technology for development of the latest clinical trial technologies and distribution of the them in industrial and academic sectors. In addition, KoNECT is organized with Steering Committee, International Advisory Board, Technical Advisory Committee, Evaluation Committee and Secretariat.
Dr Bae Byuongjun, president of the Korea National Enterprise for Clinical Trials (KoNECT), outlines why Korea stands out in the APAC region as a top clinical trial destination, how clinical…
Deborah Chee, President of KoNECT (Korea National Enterprise for Clinical Trials), discusses what it takes to build one of the world’s leading clinical trials ecosystems and highlights the importance of…
The Korea National Enterprise for Clinical Trials (KoNECT) was established in 2007 by the Korean government to meet the increasing demand for local clinical trials and strengthen the country’s clinical research…
Korea had a late start, but is now one of the global hot spots for clinical trials. How would you sum up and explain this quick evolution? Clinical trials in…
South Korea is the 12th largest healthcare market globally with a market size of around USD 20 billion in 2019. With the government’s plans to invest over USD 1.7 billion…
Multinational pharma company managers working abroad must adapt to new cultures and develop a deep understanding of local markets. Korea is no different; here three foreign country managers give their…
Industry players – from Big Pharma giants to small local startups – are bringing new, innovative solutions to market in Korea in order to try and solve the country’s diabetes…
The nation of South Korea has overtaken many of its regional counterparts to boast a highly impressive biosimilars pipeline. Here, key stakeholders in Korean biologics and biosimilars explain how. …
ISU Abxis is a biotech company founded in 2001 with a focus on orphan drugs and rare disease. Part of the ISU chaebol, ISU Abxis has leveraged its parent company’s…
CEO of the Life Science division of LG – one of Korea most recognized global brands – Dr Jeewoong Son has spent much of his career gathering the knowhow to…
One of the indisputable economic success stories of the last half-century, South Korea now stands as the world’s 11th largest economy, with a reputation for industrial excellence and innovation. As…
The Korean cosmetics market is now the 8th largest in the world, with 2.9 percent of the global market share, capitalising on the global rise in interest for Korean culture,…
SK Plasma is a blood plasma company that was spun off from SK Chemicals in 2015. Its CEO, Yun Ho Kim, offers his insights into the company’s vision to establish…
French-headquartered logistics and distribution provider Bolloré Logistics has been steadily increasing its footprint in Korean life sciences in recent years – attaining international certifications to assure potential partners of their…
Rene Wipperich took the helm of Galderma’s Korean affiliate in August 2018. He breaks down the performance of the affiliate across its four business segments and the main competitive advantages…
YD Global Life Science is a Korean biopharmaceutical company with ambitions to become a global leader in new drug development with USD 1 billion in revenues. Its founder & CEO,…
See our Cookie Privacy Policy Here
